Our previous work revealed that chrysosplenetin in combination with artemisinin inhibited in vivo P-glycoprotein (P-gp, one of classic multi-drug resistance proteins) mediated digoxin transportation activity by reversing the upregulated P-gp/Mdr1 mRNA expression levels by artemisinin. Therefore, chrysosplenetin might be a potential artemisinin-resistance reversal agent as a P-gp inhibitor. But it still remains unknown if chrysosplenetin has an impact on another pivotal multi-drug resistance protein, breast cancer resistance protein (Bcrp), which is co-expressed with P-gp in apical membrane of intestinal epithelial cell and overlaps some of the substrates and inhibitors. This study, therefore, further addressed the impact of chrysosplenetin, per se or in combination with artemisin, on Bcrp/ABCG2 mRNA expression levels in mice small intestine determined by western blot and real time-quantitative polymerase chain reaction (RT-qPCR) assay. The drugs were intragastrically administrated once per day for 7 days. Novobiocin, a known Bcrp inhibitor, was observed to have no impact on Bcrp/ABCG2 levels with or without artemisinin versus vehicle. Interestingly, artemisinin alone attenuated Bcrp level while chrysosplenetin alone increased it (p < 0.05). Relative mRNA level was significantly decreased when co-used with artemisinin and chrysosplenetin in ratio of 1:2 (p < 0.05). The discrepant results for chrysosplenetin on Bcrp/ABCG2 mRNA expressions might be closely related to the transcriptional or posttranscriptional regulation.
Alcantara, L.M., Kim, J., Moraes, C.B., Franco, C.H., Franzoi, K.D., Lee, S., Freitas-Junior, L.H., Ayong, L.S., 2013. Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites. Exp. Parasitol. 134, 235–243.
Duan, P., You, G.F., 2009. Novobiocin is a potent inhibitor for human organic anion transporters. Drug Metab. Dispos. 37, 1203–1210.
Gillet, J.P., Gottesman, M.M., 2011. Advances in the molecular detection of ABC transporters involved in multidrug resistance in cancer. Curr. Pharm. Biotechnol. 12, 686–692.
Lagas, J.S., van Waterschoot, R.A., van Tilburg, V.A., Hillebrand, M.J., Lankheet, N., Rosing, H., Beijnen, J.H., Schinkel, A.H., 2009. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment. Clin. Cancer Res. 15, 2344–2351.
Lecerf-Schmidt, F., Peres, B., Valdameri, G., Gauthier, C., Winter, E., Payen, L., Di Pietro, A., Boumendjel, A., 2013. ABCG2: recent discovery of potent and highly selective inhibitors. Future Med. Chem. 5, 1037–1045.
Ma, L.P., Wei, S.J., Yang, B., Ma, W., Wu, X.L., Ji, H.Y., Sui, H., Chen, J., 2017. Chrysosplenetin inhibits artemisinin efflux in P-gp-over-expressing Caco-2 cells and reverses P-gp/MDR1 mRNA up-regulated expression induced by artemisinin in mouse small intestine. Pharm. Biol. 55, 374–380.
Mao, Q.C., Unadkat, J.D., 2015. Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport-an update. AAPS J. 17, 65–82.
Meng, X., Liao, S., Wang, X.Y., Wang, S.X., Zhao, X.F., Jia, P., Pei, W.J., Zheng, X.P., Zheng, X.H., 2014. Reversing P-glycoprotein-mediated multidrug resistance in vitro by α-asarone and β-asarone, bioactive cis-trans isomers from Acorus tatarinowii. Biotechnol. Lett. 36, 685–691.
Meshnick, S.R., Taylor, T.E., Kamchonwongpaisan, S., 1996. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev. 60, 301–315.
Ni, Z.L., Bikadi, Z., Rosenberg, M.F., Mao, Q.C., 2010. Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr. Drug Metab. 11, 603–617.
Noguchi, K., Katayama, K., Sugimoto, Y., 2014. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers. Med. 7, 53–64.
Numonov, S.R., Qureshi, M.N., Aisa, H.A., 2015. Development of HPLC protocol and simultaneous quantification of four free flavonoids from Dracocephalum heterophyllum Benth. Int. J. Anal. Chem., https://doi.org/10.1155/2015/503139.
Shiozawa, K., Oka, M., Soda, H., Yoshikawa, M., Ikegami, Y., Tsurutani, J., Nakatomi, K., Nakamura, Y., Doi, S., Kitazaki, T., Mizuta, Y., Murase, K., Yoshida, H., Ross, D.D., Kohno, S., 2004. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int. J. Cancer 108, 146–151.
Tripathi, R., Rizici, A., Pandey, S.K., Dwivedi, H., Saxena, J.K., 2013. Ketoconazole, a cytochrome P450 inhibitor can potentiate the antimalarial action of β/β arteether against MDR Plasmodium yoelii Nigeriensis. Acta Trop. 126, 150–155.
Wei, S.J., Ji, H.Y., Yang, B., Ma, L.P., Bei, Z.C., Li, X., Dang, H.W., Yang, X.Y., Liu, C., Wu, X.L., Chen, J., 2015. Impact of chrysosplenetin on the pharmacokinetics and antimalarial efficacy of artemisinin against Plasmodium berghei as well as in vitro CYP450 enzymatic activities in rat liver microsome. Malar. J. 14, 432–445.
Wesolowska, O., 2011. Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1. Acta Biochim. Pol. 58, 433–448.
White, N.J., 2004. Antimalarial drug resistance. J. Clin. Investig. 113, 1084–1092.
Yang, B., Ma, L.P., Ma, W., Wei, S.J., Ji, H.Y., Li, H.G., Dang, H.W., Liu, C., Wu, X.L., Chen, J., 2016. A self-contrast approach to evaluate the inhibitory effect of chrysosplenetin, in the absence and presence of artemisinin on the in vivo P-glycoprotein-mediated digoxin transport activity. Biomed. Chromatogr. 30, 1582–1590.
Yuan, J., Wong, I.L., Jiang, T., Wang, S.W., Liu, T., Wen, B.J., Chow, L.M., Sheng, B.W., 2012. Synthesis of methylated quercetin derivatives and their reversal activities on P-gp and BCRP-mediated multidrug resistance tumor cells. Eur. J. Med. Chem. 54, 413–422.
WM, YZ and YZ contributed in running the laboratory work. CZ and JW analyzed the data. LM and BY revised the manuscript critically. XW and JC designed the study, supervised the laboratory work and contributed to modify the manuscript. All the authors have read the final manuscript and approved its submission.
About this article
Cite this article
Ma, W., Zhang, Y., Zhang, Y. et al. Impact of chrysosplenetin, per se or in combination with artemisinin, on breast cancer resistance protein (Bcrp)/ABCG2 mRNA expression levels in mice small intestine. Rev. Bras. Farmacogn. 27, 776–779 (2017). https://doi.org/10.1016/j.bjp.2017.06.005
- Bcrp/ABCG2 mRNA expression
- Western blot